|
| | LY411575 Basic information |
| Product Name: | LY411575 | | Synonyms: | LY411575;(aS)-N-[(1S)-2-[[(7S)-6,7-Dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-3,5-difluoro-alpha-hydroxybenzeneacetamide;(S)-2-(2-(3,5-difluorophenyl)acetaMido)-N-((S)-5-Methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl)propanaMide;Benzeneacetamide, N-[(1S)-2-[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-3,5-difluoro-α-hydroxy-, (αS)-;(aS)-N-[(1S)-2-[[(7S)-6,7-Dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-3,5-difluoro-alpha-hydroxybenzeneacetamide LY 411575;LY 411575 (aS)-N-[(1S)-2-[[(7S)-6,7-Dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-3,5-difluoro-alpha-hydroxybenzeneacetamide;LSN-411575;N2-[(2S)-2-(3,5-Difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide | | CAS: | 209984-57-6 | | MF: | C26H23F2N3O4 | | MW: | 479.48 | | EINECS: | | | Product Categories: | Inhibitor;Inhibitors | | Mol File: | 209984-57-6.mol |  |
| | LY411575 Chemical Properties |
| Boiling point | 836.0±65.0 °C(Predicted) | | density | 1.40 | | storage temp. | -20°C | | solubility | DMSO: soluble5mg/mL, clear | | pka | 11.79±0.20(Predicted) | | form | powder | | color | white to beige | | InChIKey | ULSSJYNJIZWPSB-CVRXJBIPSA-N |
| Safety Statements | 24/25 | | WGK Germany | 3 | | HS Code | 29337900 |
| | LY411575 Usage And Synthesis |
| Description | γ-Secretase is a multi-subunit aspartyl protease that regulates signaling pathways by proteolytically cleaving substrates, abrogating or releasing signaling molecules. One well-known substrate of this enzyme is Notch, a transmembrane receptor that plays a key role in cell fate decisions including cell proliferation, differentiation, and apoptosis. LY411575 is a cell-permeable γ-secretase inhibitor (IC50 = 0.14 nM) that has been shown to block Notch activation in vitro at 500 μM. LY411575 can induce apoptosis in Kaposi’s sarcoma cells as well as promote intestinal goblet cell differentiation in a mouse model of colitis. It has also been observed to promote neural differentiation of mouse embryonic stem cells. | | Uses | LY-411575 has been used as a potent γ-secretase inhibitor and Notch inhibitor. | | Definition | ChEBI: A dibenzoazepine that is 5,7-dihydro-6H-dibenzo[b,d]azepin-6-one which is substituted at the 7 pro-S position by the C-terminal carboxamide nitrogen of N
/element>2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]-L-alaninamide. It is a potent, cell permeable and selective gamma-secretase inhibitor. It has been tested as a possible treatment
for Alzheimer's disease and shows promise for its potential to counteract severe hearing loss. | | Biochem/physiol Actions | LY-411575 is potent, cell permeable and selective γ-secretase inhibitor that reduces Aβ/42 after acute or chronic treatment, and blocks Notch activation. Studies (Cancer Cell) have shown that treatment with LSN-411575 arrests KrasG12V-driven NSCLCs in association with inhibition of HES1 expression and ERK phosphorylation. | | target | γ-secretase |
| | LY411575 Preparation Products And Raw materials |
|